Augmentin ES-600 Label Places Limit On Use For Penicillin-Resistant Strains
Executive Summary
GlaxoSmithKline's Augmentin ES-600 labeling for otitis media sets a limit on the S. pneumoniae penicillin-resistant strains the antibiotic is expected to effectively treat.
You may also be interested in...
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions
GSK Augmentin ES Conversion Rate Reaches 31%; XR Filing Imminent
GlaxoSmithKline is converting about one-third of Augmentin suspension Rxs to the ES-600 formulation, GSK Chief Operating Officer Bob Ingram told securities analysts Feb. 14